Tectonic Therapeutic plans to launch a Phase 2 clinical trial to test the impact of its therapy candidate TX45 on blood flow, or hemodynamics, in people with pulmonary hypertension and interstitial lung disease (PH-ILD). The move comes on the heels of positive results from part A of a…
News
People with portopulmonary hypertension (PoPH), a form of pulmonary arterial hypertension (PAH) usually associated with liver disease, show lower five-year survival rates than people with other types of PAH. Common markers that help predict outcomes in other PAH forms failed to identify high-risk patients in this group, however. But…
A 5-year-old boy with a neuroblastoma developed pulmonary arterial hypertension (PAH) after receiving high-dose busulfan to prepare for a stem cell transplant, but diagnosing his condition early and treating it with three lung pressure-lowering medications led to a full recovery. This treatment approach has significantly increased survival in children…
The degree of tricuspid regurgitation (TR), a cardiac abnormality detected in a heart ultrasound, may help predict the outcomes in people with pulmonary arterial hypertension (PAH), a study suggests. Those with more advanced TR were at a higher risk of death. This relationship was seen specifically in the subgroup…
Having pulmonary hypertension (PH) increases the risk of death, both in the short and long term, for individuals undergoing surgery for the heart valve disease aortic stenosis, a new analysis of published studies has found. Noting the older age, generally, of people with aortic stenosis undergoing the procedure, the…
Researchers identified two genes — PRDX1 and TNFAIP3 — whose activity levels could serve as diagnostic biomarkers for idiopathic pulmonary arterial hypertension (PAH). The genes are related to ferroptosis, an iron-dependent type of cell death involved in lung diseases and previously associated with PAH. “Our comprehensive analysis…
Exosomes — very small, sac-like structures — derived from stem cells may offer a potential treatment for hypoxic pulmonary hypertension (HPH) by preventing the abnormal growth and movement of muscle cells lining blood vessels. That’s according to data from a new study, conducted by researchers in China using lab-grown…
Among U.S. healthcare providers who treat pulmonary arterial hypertension (PAH), a patient’s current treatment, PAH cause, and coexisting health issues are the factors that most influence their willingness to prescribe first-line combination therapy over monotherapy, according to a new study. Most clinicians said they felt a single tablet combination…
Treatment with inhaled nitric oxide (iNO) and pulmonary surfactant within the first three days of life significantly reduces the risk of developing bronchopulmonary dysplasia (BPD) associated with pulmonary hypertension (PH) in preterm infants, according to a recent study in China. “Early intervention using iNO and PS appears to be…
Most people with pulmonary arterial hypertension (PAH) are not referred for a lung transplant, despite clinical recommendations that referral should occur early in potentially eligible cases, a study reports. About 18% to 29% of participants with advanced functional class 4 disease, who guidelines recommend referrals for, received referrals.
Boosting the levels of irisin, a protein found at lower levels in people with pulmonary arterial hypertension (PAH), may help slow disease progression by stopping abnormal cell growth and blood vessel remodeling in the lungs, a study has found. “[I]risin is a novel protective factor against PAH development and is…
Elevated blood levels of a protein called CTRP7 — which are significantly higher in people with pulmonary arterial hypertension (PAH) than in those without the disease — may predict a poor response to Uptravi (selexipag), according to findings from a new study in Japan involving both mice and…
